Fulcrum Therapeutics Valuation Analysis

Stocks USA . 
Stock . Fulcrum Therapeutics
Fulcrum Therapeutics is priced without meaningful earnings support relative to broader benchmarks, shaped by the current earnings and balance-sheet profile. Fulcrum Therapeutics trades at 1.47x book value. Combined equity and net debt push enterprise value to 139.7 M on a 467.8 M market cap.

Valuation Framework, Methodology & Assumptions

Fulcrum Therapeutics is a small-cap equity in NASDAQ Biotechnology category. Capital structure affects intrinsic modeling assumptions. Current valuation multiples for Fulcrum Therapeutics include P/S of 6.06, enterprise value (TTM) of 139.65 million, P/B of 1.47.

Fulcrum Therapeutics analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. Valuation outputs are model-derived and depend on published assumptions and reference inputs.

The analysis above is generated by quantitative models and is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an endorsement to buy or sell any security. All investing involves risk, including the possible loss of principal. Consult a qualified financial advisor before making investment decisions. See our Terms of Use for full details.

Financial data referenced in this analysis is derived from publicly available SEC filings, audited financial statements, and third-party market data providers. The intrinsic value estimate is generated by Macroaxis quantitative models that incorporate fundamental analysis, technical indicators, and risk metrics.

The methodology combines multiple analytical inputs:

  • Fundamental analysis - financial statements, profitability ratios, debt structure, and cash flow metrics sourced from SEC filings and public financial reports
  • Technical indicators - historical price patterns, momentum signals, and volatility measures
  • Risk assessment - probability of bankruptcy models, market risk metrics, and downside scenario analysis
  • Peer comparison - relative valuation against industry peers using standardized multiples

Model outputs are refreshed periodically as new financial data becomes available. Past model performance is not indicative of future results. The intrinsic value estimate reflects a point-in-time calculation and should be considered alongside other research and professional advice.

Data sourced from SEC filings (EDGAR), public financial statements, and market data providers.

Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board
Fulcrum Therapeutics has a market cap of 467.77 million, current ratio of 15.49. Quarter-over-quarter changes in these metrics are often more informative than the current snapshot. Broader economic conditions can influence Fulcrum Therapeutics's company valuation - related indicators include signals in rate.
Fulcrum Therapeutics currently shows ROE of -27.1%, market cap of USD 467.77 million. This analysis of Fulcrum Therapeutics works best as a complementary layer in the context of analysis of how the security fits in a broader portfolio. Fulcrum Therapeutics analysis across multiple dimensions - risk, valuation, diversification - produces a more complete analytical picture. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Related Tools for Fulcrum Stock

Fulcrum Therapeutics market performance reflects earnings consistency and capital efficiency.
Portfolio AnywhereTrack or share privately all of your investments from the convenience of any devicePortfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capitalInvesting OpportunitiesExplore predefined thematic ideas and evaluate them within your portfolio contextIdea BreakdownAnalyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themesPattern RecognitionUse different Pattern Recognition models to identify potential trend changes across multiple global exchangesCrypto CorrelationsMeasure how cryptocurrency returns move relative to each other to evaluate portfolio diversificationPositions RatingsView algorithmic ratings for individual portfolio positions based on fundamental analysis and risk-adjusted market performanceStock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.Price Exposure ProbabilityAnalyze equity upside and downside potential for a given time horizon across multiple markets
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.